Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713375 | 0.72 | ALOX5 (0.42) | KMT2AMAPTGAA | |
| SCHEMBL1398550 | 0.71 | MMP12 (0.40) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL88746 | 0.69 | MMP12 (0.58) | MMP12PARP1AHRPDK2ALDH1A1 | |
| SCHEMBL4087192 | 0.69 | — | — | |
| SCHEMBL14931707 | 0.69 | DRD2 (0.43) | — | |
| SCHEMBL8645699 | 0.68 | MAOA (0.50) | MMP12PARP1AHRPDK2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6518631 | 0.68 | MMP12 (0.56) | MMP12PARP1AHRPDK2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30293243 | 0.68 | MMP12 (0.56) | MMP12PARP1AHRPDK2ALDH1A1 | |
| SCHEMBL791635 | 0.68 | AHR (0.48) | AHRPDK2ALDH1A1KMT2ANPC1 | |
| SCHEMBL2090031 | 0.67 | NPC1 (0.50) | AHRPDK2CYP11B1CYP11B2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127062-A | Thiadiazolyl derivatives as inhibitors of DNA polymerase Theta | 伊迪亚生物科学有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-02-13 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | claimed |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | Epizyme, Inc. (US) | 2017-08-31 | — | — | US | claimed |
| EP-3193600-A1 | SMYD INHIBITORS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| EP-3193609-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016040505-A1 | SMYD INHIBITORS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | claimed |
| WO-2016040508-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | claimed |
| US-6660732-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | claimed |
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | claimed |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| JP-2002539198-A | — | — | 2002-11-19 | — | — | JP | claimed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | claimed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | claimed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | MPO, EPX, PTGES | MMP12 278/4885PARP1 2002/4885AHR 92/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | MMP12 4024/4885PARP1 4579/4885AHR 2465/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | MMP12 4029/4885PARP1 4583/4885AHR 2472/4885 |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | SMYD3, SMYD2, SMURF2 | MMP12 4455/4885PARP1 3438/4885AHR 3247/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | MMP12 4356/4885PARP1 4650/4885AHR 1942/4885 |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SMURF2 | MMP12 4455/4885PARP1 3438/4885AHR 3247/4885 |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | TNF, IL2, IL1B | MMP12 71/4885PARP1 2664/4885AHR 523/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | MMP12 133/4885PARP1 2776/4885AHR 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.